Upsized and target-topping Bay Area biotech IPO scores $252M

Nkarta Inc. raised $252 million in an IPO that sold more shares than expected and at a higher price than the targets it boosted just a day earlier. The South San Francisco company is the seventh life sciences IPO from the region in a year when there has yet to be a Wall Street debut by a native Bay Area tech company. At least four more are expected this month. Nkarta sold 14 million shares at $18. It was expected to sell 13 million shares for between $16 and $17 each. Underwriters have the option…